Clinical Trial Update: A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer [Phase 1]

View source ↗

Summary

A Phase 1 study evaluated pharmacokinetics and safety of the Budesonide/Glycopyrronium/Formoterol metered-dose inhaler (BGF MDI) using a next-generation propell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• BGF MDI (budesonide/glycopyrronium/formoterol) (budesonide; glycopyrronium; formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease | Phase 1 | Status: COMPLETED